We further discuss the preclinical rationale and emerging clinical data of all the different therapeutic approaches targeting IDH1/2-mut in gliomas, including inhibitors blocking the mut enzyme, immunotherapy, and agents exploiting cellular metabolic and epigenetic vulnerabilities associated with IDH-mut phenotype (Figure 1). Here, IDH2 is linked to glioma.